A nasal spray with a potassium channel blocker relieved nocturnal apnea
A clinical trial by Australian scientists found that the selective potassium channel blocker TASK 1/3, which increases upper airway dilator muscle activity and reduces pharyngeal spasm, reduced the severity of obstructive sleep apnea
19.03.2024